FGFR4 and CDK4/6 Inhibitor Combination for HCC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHCC) lack effective solutions, particularly in addressing the overactivation of signaling pathways such as FGF19/FGFR4 and CDK4/6, which contribute to tumor growth and progression.
Innovation Solution
A combination therapy involving a selective FGFR4 inhibitor, Compound 1, and a CDK4/6 inhibitor, such as ribociclib or palbociclib, administered orally to inhibit tumor growth by targeting these pathways simultaneously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy with Compound 1 and CDK4/6 inhibitor is used, then antitumor effect is enhanced, but treatment complexity increases
Solution Approach 1:
The patent combines Compound 1 (FGFR4 inhibitor) with CDK4/6 inhibitors in a single treatment regimen, merging two therapeutic agents that target different signaling pathways (FGF19/FGFR4 and CDK4/6) to achieve synergistic antitumor effects while managing the complexity through coordinated administration protocols
2Volume of moving object
If combination therapy with Compound 1 and CDK4/6 inhibitor is used, then tumor volume reduction is increased, but dosage optimization difficulty increases
Solution Approach 1:
The patent systematically varies the dosage parameters of Compound 1 and CDK4/6 inhibitors to identify optimal treatment regimens, adjusting concentrations and administration schedules to maximize tumor volume reduction while establishing standardized dosage protocols to manage optimization complexity
Data Source
Figure 1A~1B
Figure 1C
Figure 2A~2B
AI summary
Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma and/or intrahepatic cholangiocarcinoma. The combination comprises an FGFR4 inhibitor and a CDK 4/6 inhibitor.